Multiplex Assay Kit for Atrial Natriuretic Peptide (ANP) ,etc. by FLIA (Flow Luminescence Immunoassay) Rhesus monkey (Simian) Multiplex ELISA

ANH; ANF; CDD; Atrial Natriuretic Factor; Atrial Natriuretic Hormone; Atriopeptin; Cardionatrine; Cardiodilatin

(Note: Up to 8-plex in one testing reaction)

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Multiplex Assay Kit for Atrial Natriuretic Peptide (ANP) ,etc. by FLIA (Flow Luminescence Immunoassay) Packages (Simulation)
  • Multiplex Assay Kit for Atrial Natriuretic Peptide (ANP) ,etc. by FLIA (Flow Luminescence Immunoassay) Packages (Simulation)
  • Multiplex Assay Kit for Atrial Natriuretic Peptide (ANP) ,etc. by FLIA (Flow Luminescence Immunoassay) Results demonstration
  • LMA225Si.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Atrial Natriuretic Peptide (ANP) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Atrial Natriuretic Peptide (ANP) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 78-98 83
EDTA plasma(n=5) 96-104 101
heparin plasma(n=5) 84-98 95

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Atrial Natriuretic Peptide (ANP) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Atrial Natriuretic Peptide (ANP) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Atrial Natriuretic Peptide (ANP) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 83-98% 82-90% 86-102% 91-101%
EDTA plasma(n=5) 86-102% 82-92% 98-105% 78-102%
heparin plasma(n=5) 88-97% 93-101% 81-88% 86-93%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:ANP) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 50μL standard or sample to each well,
    add 10μL magnetic beads,and 50μL Detection Reagent A,incubate 60min at 37°C on shaker;
3. Wash plate on magnetic frame for three times;
4. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
5. Wash plate on magnetic frame for three times;
6. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

Multiplex Assay Kit for Atrial Natriuretic Peptide (ANP) ,etc. by FLIA (Flow Luminescence Immunoassay)

Test principle

Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards,Labeled antigen and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest.A competitive inhibition reaction is launched between biotin labeled analytes of interest and unlabeled analytes of interest (Standards or samples) with the pre-coated antibody specific to analytes of interest. Following a wash to remove any unbound substances, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE) is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer. The MFI developed is reverse proportional to the concentration of analytes of interest in the sample.

Giveaways

Increment services

Citations

  • Volume Status and Diuretic Therapy in Systolic Heart Failure and the Detection of Early Abnormalities in Renal and Tubular FunctionPubMed: 21616283
  • Release of atrial natriuretic peptide precedes shedding of the endothelial glycocalyx equally in patients undergoing on- and off-pump coronary artery bypass surgeryPubMed: 21769675
  • Atrial natriuretic Peptide, arginine vasopressin Peptide and cortisol serum levels in opiate-dependent patientsPubMed: 23406607
  • Alcohol-induced changes in methylation status of individual CpG sites, and serum levels of vasopressin and atrial natriuretic peptide in alcohol-dependent patients during detoxification treatment.Pubmed: 24356727
  • Hypervolemia increases release of atrial natriuretic peptide and shedding of the endothelial glycocalyxPubmed:25497357
  • Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes.Pubmed:26927445
  • Danhong injection attenuates isoproterenol-induced cardiac hypertrophy by reCavia (Guinea pig )lating p38 and NF-κb pathwayPubmed:26970569
  • Blood Pressure and Atrial Natriuretic Peptide (ANP) Levels in Patients with Autosomal Dominant Polycystic Kidney Disease.papers:uobj_paper_2016_62613672.pdf
  • Enhanced heart failure, mortality and renin activation in female mice with experimental dilated cardiomyopathypubmed:29240788
  • Ginsenoside Rg3 micelles mitigate doxorubicin-induced cardiotoxicity and enhance its anticancer efficacy.pubmed:29063791
  • SIRT2 deacetylase regulates the activity of GSK3 isoforms independent of inhibitory phosphorylationPubmed:29504933
  • Co-exposure of silica nanoparticles and methylmercury induced cardiac toxicity andPubmed:29727991
  • Toll-like receptor 2 deficiency hyperactivates the FoxO1 transcription factor and induces aging-associated cardiac dysfunction in micePubmed:29929978
  • Determinants of Increased Aortic Diameters in Young Normotensive Patients With Turner Syndrome Without Structural Heart DiseasePubmed:29392348
  • Signature-oriented investigation of the efficacy of multicomponent drugs against heart failurePubmed: 30230922
  • Endothelin-1 (ET-1), N-terminal fragment of proatrial natriuretic peptide (NTpro-ANP) and tumor necrosis factor alpha (TNF-α) in children with primary hypertension …Pubmed: 30359461
  • ANP/NPRA Inhibits Epithelial-Mesenchymal Transition of Airway by Targeting Smad3 in Asthma
  • Relationship between Natriuretic Peptide Levels with Heart and Kidney Parameters in Rats with Chronic Renal Failure.
  • The poly (ADP-ribosyl) ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy34094834
  • Alarin moderated myocardial hypertrophy via inhibiting cyclic adenosine monophosphate/protein kinase A signaling pathway to attenuate autophagy34624429
  • Osteocrin alleviates cardiac hypertrophy via attenuating oxidative stressPubmed:35218795

Recommend products